<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03824990</url>
  </required_header>
  <id_info>
    <org_study_id>NMU-FY2018-72</org_study_id>
    <nct_id>NCT03824990</nct_id>
  </id_info>
  <brief_title>Multi-center Clinical Study on Neonatal Hyperbilirubinemia</brief_title>
  <official_title>Multi-center Clinical Study on Early Screening and Treatment of Hyperbilirubinemia of Term and Late-preterm Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JiLin Women and Children Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shan Dong Qian Fo Shan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shan Dong Liao Cheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwest Women's and Children's Hospital, Xi'an, Shaanxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yin Chuan Maternity and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eight hospitals in China will participate in the study, which aims to decrease the incidence
      of severe hyperbilirubinemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Through a prospective cohort study of healthy term and near-term infants, the study tries to
      truly reflect the epidemiology, intervention status, and outcomes of neonatal
      hyperbilirubinemia and the cost. Hopefully, by improving the quality of management of
      neonatal jaundice,we can explore and obtain a healthy term and near-term jaundice management
      model suitable for China's national condition, which can eventually reduce the incidence rate
      of neonatal severe hyperbilirubinemia and bilirubin encephalopathy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of bilirubin encephalopathy</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe hyperbilirubinemia</measure>
    <time_frame>18 months</time_frame>
    <description>Severe hyperbilirubinemia:total serum bilirubin more than 20mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of lost to follow-up</measure>
    <time_frame>18 months</time_frame>
    <description>The rate of lost to follow-up for jaundice after discharge from well-baby nursery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse neurological outcomes in patients with severe hyperbilirubinemia</measure>
    <time_frame>42 months</time_frame>
    <description>Patients with severe hyperbilirubinemia from 11 hospitals will be followed to investigate their neurological outcomes until 24 months after birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical costs in patients with severe hyperbilirubinemia</measure>
    <time_frame>18 months</time_frame>
    <description>To compare the medical costs in patients with severe hyperbilirubinemia from 3 phases of quality improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Quality Improvement</condition>
  <condition>Hyperbilirubinemia, Neonatal</condition>
  <arm_group>
    <arm_group_label>Before-intervention phase</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All the healthy infants who were admitted from March 2018 to August 2018 to the Well Baby nurse of different hospitals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the healthy infants who were admitted from September 2018 to February 2019 to the Well Baby nurse of different hospitals.During this phase,multiple intervention bundles of quality improvement will be implemented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sustainability intervention phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the healthy infants who were admitted from March 2019 to August 2019 to the Well Baby nurse of different hospitals.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality improvement of management of neonatal jaundice</intervention_name>
    <description>During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.</description>
    <arm_group_label>Intervention phase</arm_group_label>
    <arm_group_label>Sustainability intervention phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        term or near-term neonates with gestational age ≥35w and birth weight ≥2000g.

        Exclusion Criteria:

        Infants admitted to a higher level of intervention before discharge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuping Han, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Nanjing Maternity and Child Health Care Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhangbin Yu, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Maternity and Child Health Care Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiyong Sun, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JiLin Women and Children Health Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haiyan Cai, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qinhuangdao Maternal and Child Health Care Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yonghui Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Yuan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shan Dong Qian Fo Shan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Qian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shan Dong Liao Cheng Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jimei Wang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrics &amp; Gynecology Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wenyan Tang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangxi Maternal and Child Health Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiufen Wei, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Maternal and Child Health Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhankui Li, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwest Women's and Children's Hospital, Xi'an, Shaanxi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Gu, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yin Chuan Maternity and Child Health Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing Maternity and Child Health Care Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Zhangbin Yu</investigator_full_name>
    <investigator_title>Nan Jing Maternity and Child Health Care Hospital</investigator_title>
  </responsible_party>
  <keyword>Quality improvement</keyword>
  <keyword>Hyperbilirubinemia</keyword>
  <keyword>screening</keyword>
  <keyword>follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

